At a glance
ClinicalIndex Comparison RecordPhase 2Active· 155 target
Drug / intervention
C019199 +1 moredrug
Likely dose
Sintilimab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating C019199 and Sintilimab for Solid Tumor. Active but no longer recruiting, targeting 155 participants across 2 sites.
Detailed Summary
This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Active
202420252026
Enrollment StartJul 2023
First PostedJan 2024
TodayJul 2026
Primary CompletionAug 2026
First PostedJan 23, 2024
Enrollment StartJul 19, 2023
Primary CompletionAug 30, 2026
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 2.4 years agoPrimary completion in 2 months
Interventions
C019199drug
The C019199 will be taken orally, once a day
Sintilimabdrug
Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.